Obesity Treatment Outcomes with Semaglutide or Tirzepatide
This original research article examines the real-world effectiveness of semaglutide and tirzepatide for obesity treatment, focusing on how medication discontinuation impacts weight loss and glycemic control. The retrospective cohort study analyzed electronic health records from a large patient population in Ohio and Florida. It reveals that discontinuation of these pharmacotherapies is common and significantly reduces the average weight reduction and improvement in glycated hemoglobin levels compared to continuous treatment. The findings suggest that maintaining […]
STAT+: Pharmalittle: We’re reading about Spain probing Novo weight loss ads, AstraZeneca stock listing, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is already upon us. After all, we have made it this far so we have decided to hang on for another couple of days. And why not? Given the likely alternatives, this seems to […]
India’s Biocon aims to lead copycat Wegovy sales in Canada from next year
Biocon Ltd is expected to be the first to launch a semaglutide copycat drug in Canada. (Upstox pic) BENGALURU: Biocon Ltd plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key markets as it races to be among the first few to reap a windfall after patents […]
Could China’s New GLP-1 Drugs Beat Out Ozempic? – Scientific American
Could China’s New GLP-1 Drugs Beat Out Ozempic? Scientific American
5 GLP-1 updates
As GLP-1 medications including Wegovy, Ozempic, Mounjaro and Zepbound reshape diabetes and weight loss care, recent developments such as new partnerships, safety questions and challenges in patient persistence show the landscape is quickly changing. Here are five recent GLP-1 developments: Novo Nordisk teams with WeightWatchers to simplify Wegovy access As of July 1, Novo Nordisk […]
China clears mazdutide as first dual GCG/GLP-1RA for weight loss
Innovent Biologics Inc. announced June 27 that it gained National Medical Products Administration’s (NMPA) approval of mazdutide as a new weight loss therapy for obese or overweight patients in China. Mazdutide is a dual glucagon/glucagon-like peptide-1 (GCG/GLP-1) receptor agonist originally discovered by Eli Lilly and Co., of Indianapolis.
Degree of weight loss affects tirzepatide-linked cardiometabolic risk improvement: Study
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study published online June 24 in the Annals of Internal Medicine.